AR080373A1 - Antagonistas de ccr3 de arilsulfamida isotopicamente enriquecida - Google Patents
Antagonistas de ccr3 de arilsulfamida isotopicamente enriquecidaInfo
- Publication number
- AR080373A1 AR080373A1 ARP110100657A ARP110100657A AR080373A1 AR 080373 A1 AR080373 A1 AR 080373A1 AR P110100657 A ARP110100657 A AR P110100657A AR P110100657 A ARP110100657 A AR P110100657A AR 080373 A1 AR080373 A1 AR 080373A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclyl
- nr1br1c
- nrbrc
- heteroaryl
- nrfrg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Arilsulfonamidas isotopicamente enriquecidas, por ejemplo, de la formula 1, que son de utilidad para modular la actividad de CCR3 y sus composiciones farmacéuticas. También, métodos de uso para tratar, prevenir o mejorar uno o varios síntomas de un trastorno, enfermedad o condicion patologica mediados por CCR3. 1. Reivindicacion 1: Un compuesto caracterizado por la formula (1) o un enantiomero, una mezcla de enantiomeros, una mezcla de dos o más diastereomeros, un tautomero o una mezcla de dos o más tautomeros de ellos; o una de sus sales, solvatos, hidratos o profármacos farmacéuticamente aceptables; en donde: R1, R2, R3, R4, R5 y R8 son cada uno, de modo independiente (a) hidrogeno, deuterio, halo, ciano, nitro o guanidina; (b) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo o heterociclilo; o (c) -C(O)R1a, -C(O)OR1a, -C(O)NR1bR1c, -C(NR1a)NR1bR1c, -OR1a, -OC(O)R1a, -OC(O)OR1a, -OC(O)NR1bR1c, -OC(=NR1a)NR1bR1c, -OS(O)R1a, -OS(O)2R1a, -OS(O)NR1bR1c, -OS(O)2NR1bR1c, -NR1bR1c, -NR1aC(O)R1d, -NR1aC(O)OR1d, -NR1aC(O)NR1bR1c, - NR1aC(=NR1d)NR1bR1c, -NR1aS(O)R1d, -NR1aS(O)2R1d, -NR1aS(O)NR1bR1c, -NR1aS(O)2NR1bR1c, -SR1a, -S(O)R1a, -S(O)2R1a, -S(O)NR1bR1c o -S(O)2NR1bR1c; R6, R7 y R9 son cada uno, de modo independiente (a) hidrogeno o deuterio; R10 y R11 son cada uno, de modo independiente (a) hidrogeno; o (b) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo o heterociclilo; o R10 y R11 se unen para formar heterociclilo; R12 es (a) hidrogeno; (b) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo o heterociclilo; o (c) -C(O)R1a, -C(O)OR1a, -C(O)NR1bR1c, -C(NR1a)NR1bR1c, -S(O)R1a, -S(O)2R1a, -S(O)NR1bR1c o -S(O)2NR1bR1c; L es alquileno C1-6; X es O o S; y cada R1a, R1b, R1c y R1d es, de modo independiente, hidrogeno, deuterio, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo o heterociclilo; o cada par de R1b y R1c junto con el átomo de N al que están unidos forman, de modo independiente, heteroarilo o heterociclilo; en donde el compuesto está isotopicamente enriquecido; en donde cada alquilo, alquileno, alquenilo, alquinilo, cicloalquilo, arilo, aralquilo, heterociclilo y heteroarilo en R1, R2, R3, R4, R5, R8, R10, R11, R12, R1a, R1b, R1c, R1d o L está opcionalmente sustituido con uno o varios sustituyentes Q, en donde cada Q está seleccionado, de modo independiente, de (a) deuterio, ciano, halo y nitro; (b) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo y heterociclilo, cada uno de los cuales está también opcionalmente sustituido con uno o varios, en una forma de realizacion, uno, dos, tres o cuatro sustituyentes Qa y (c) -C(O)Ra, -C(O)ORa, -C(O)NRbRc, -C(NRa)NRbRc, -ORa, -OC(O)Ra, -OC(O)ORa, -OC(O)NRbRc, -OC(=NRa)NRbRc, -OS(O)Ra, -OS(O)2Ra, -OS(O)NRbRc, -OS(O)2NRbRc, -NRbRc, -NRaC(O)Rd, -NRaC(O)ORd, -NRaC(O)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(O)Rd, -NRaS(O)2Rd, -NRaS(O)NRbRc, -NRaS(O)2NRbRc, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRbRc y -S(O)2NRbRc, en donde cada Ra, Rb, Rc y Rd es, de modo independiente, (i) hidrogeno o deuterio; (ii) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo o heterociclilo, cada uno opcionalmente sustituido con uno o varios, en una forma de realizacion, uno, dos, tres o cuatro, sustituyentes Qa; o (iii) cada par de Rb y Rc junto con el átomo de N al que están unidos forman heterociclilo, opcionalmente sustituido con uno o varios, en una forma de realizacion, uno, dos, tres o cuatro, sustituyentes Qa; en donde cada Qa está seleccionado, de modo independiente, del grupo que consiste en (a) deuterio, ciano, halo y nitro; (b) alquilo C1-6, alquenilo C2-6, alquinilo C2- 6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo y heterociclilo; y (c) -C(O)Re, -C(O)ORe, -C(O)NRfRg, -ORe, -OC(O)Re, -OC(O)ORe, -OC(O)NRfRg, -OC(=NRe)NRfRg, -OS(O)Re, -OS(O)2Re, -OS(O)NRfRg, -OS(O)2NRfRg, -NRfRg, -NReC(O)Rh, -NReC(O)ORf, -NReC(O)NRfRg, -NReC(=NRh)NRfRg, -NReS(O)Rh, -NReS(O)2Rh, -NRes(O)NRfRg, -NReS(O)2NRfRg, -SRe, -S(O)Re, -S(O)2Re, -S(O)NRfRg y -S(O)2NRfRg, en donde cada Re, Rf, Rg y Rh es, de modo independiente, (i) hidrogeno o deuterio; (ii) alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, aralquilo C7-15, heteroarilo o heterociclilo; o (iii) cada par de Rf y Rg junto con el átomo de N al que están unidos forman heterociclilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30981510P | 2010-03-02 | 2010-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080373A1 true AR080373A1 (es) | 2012-04-04 |
Family
ID=43903983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100657A AR080373A1 (es) | 2010-03-02 | 2011-03-02 | Antagonistas de ccr3 de arilsulfamida isotopicamente enriquecida |
Country Status (11)
Country | Link |
---|---|
US (1) | US8999995B2 (es) |
EP (1) | EP2542542B1 (es) |
AR (1) | AR080373A1 (es) |
AU (1) | AU2011223873B2 (es) |
CA (1) | CA2791964A1 (es) |
DK (1) | DK2542542T3 (es) |
ES (1) | ES2542404T3 (es) |
HK (1) | HK1180334A1 (es) |
HU (1) | HUE025699T2 (es) |
TW (1) | TWI485139B (es) |
WO (1) | WO2011109345A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298786B (zh) * | 2010-10-11 | 2016-01-20 | 埃克希金医药品有限公司 | 芳基磺酰胺盐ccr3拮抗剂 |
CN104781240A (zh) * | 2012-09-07 | 2015-07-15 | 埃克希金医药品有限公司 | 同位素富集的芳基磺酰胺ccr3拮抗剂 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
EP1007012A4 (en) | 1996-10-01 | 2006-01-18 | Cima Labs Inc | TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
CA2520225C (en) | 2003-03-24 | 2014-08-12 | Bayer Healthcare Ag | Benzenesulfonamide derivatives |
WO2008063600A2 (en) | 2006-11-17 | 2008-05-29 | Concert Pharmaceuticals Inc. | Triazolyl tropane derivatives |
KR101687144B1 (ko) * | 2009-04-22 | 2016-12-15 | 액시킨 파마수티컬스 인코포레이티드 | 2,5-이치환된 아릴설폰아마이드 ccr3 길항제 |
DK2421829T3 (en) * | 2009-04-22 | 2016-01-04 | Axikin Pharmaceuticals Inc | 2,5-disubstituted aryl sulfonamide CCR3 antagonists |
EP2502921B1 (en) * | 2009-04-22 | 2015-05-20 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
CN103298786B (zh) * | 2010-10-11 | 2016-01-20 | 埃克希金医药品有限公司 | 芳基磺酰胺盐ccr3拮抗剂 |
-
2011
- 2011-03-01 ES ES11707755.2T patent/ES2542404T3/es active Active
- 2011-03-01 WO PCT/US2011/026612 patent/WO2011109345A1/en active Application Filing
- 2011-03-01 EP EP20110707755 patent/EP2542542B1/en not_active Not-in-force
- 2011-03-01 DK DK11707755.2T patent/DK2542542T3/en active
- 2011-03-01 US US13/038,251 patent/US8999995B2/en not_active Expired - Fee Related
- 2011-03-01 CA CA2791964A patent/CA2791964A1/en not_active Abandoned
- 2011-03-01 HU HUE11707755A patent/HUE025699T2/en unknown
- 2011-03-01 AU AU2011223873A patent/AU2011223873B2/en not_active Ceased
- 2011-03-02 AR ARP110100657A patent/AR080373A1/es unknown
- 2011-03-02 TW TW100106955A patent/TWI485139B/zh not_active IP Right Cessation
-
2013
- 2013-07-02 HK HK13107672.5A patent/HK1180334A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2542542B1 (en) | 2015-04-22 |
US8999995B2 (en) | 2015-04-07 |
US20110218207A1 (en) | 2011-09-08 |
EP2542542A1 (en) | 2013-01-09 |
HUE025699T2 (en) | 2016-04-28 |
AU2011223873A1 (en) | 2012-09-20 |
AU2011223873B2 (en) | 2015-06-25 |
ES2542404T3 (es) | 2015-08-05 |
CA2791964A1 (en) | 2011-09-09 |
TW201136899A (en) | 2011-11-01 |
WO2011109345A1 (en) | 2011-09-09 |
TWI485139B (zh) | 2015-05-21 |
DK2542542T3 (en) | 2015-07-20 |
HK1180334A1 (en) | 2013-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080945A1 (es) | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
AR083946A1 (es) | Metodos de tratamiento con inhibidores selectivos de bcl-2 | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
AR080770A1 (es) | Piperidinsulfonamidas moduladoras de la actividad de receptores xcc3, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de patologias respiratorias,tales como asma, entre otras. | |
AR098912A1 (es) | Inhibidores de syk | |
AR075974A1 (es) | Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer | |
AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR098048A1 (es) | Inhibidores de fgfr4 | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
CU24363B1 (es) | Compuestos peptidomiméticos cíclicos | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR092045A1 (es) | Combinaciones farmaceuticas | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR079510A1 (es) | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. | |
AR083383A1 (es) | Sales de antagonistas de ccr3 de arilsulfonamida | |
AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
AR087211A1 (es) | ANTAGONISTAS DE CRTh2 | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |